EUVIMEDEUVIMED entdecken
Crossref

Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2

Hong Yu, Liam J Worrall iD, Thorsten Berger, Martin Petric, Bryan H Lin iD, Marija Vuckovic iD, Craig S Robb iD, Quan Le, Calem Kenward iD, Chuanbin Dai, Andrew Wakeham, Shaofeng Liu und 19 weitere

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2300282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Hong Yu und 30 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Centre for Disease Control, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: COVID-19, Viral Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current vaccine efforts to combat SARS-CoV-2 are focused on the whole spike protein administered as mRNA, viral vector, or protein subunit. However, the SARS-CoV-2 receptor-binding domain (RBD) is the immunodominant portion of the spike protein, accounting for 90% of serum neutralizing activity. In this study, we constructed several versions of RBD and together with aluminum hydroxide or DDA (dimethyldioctadecylammonium bromide)/TDB (d-(+)-trehalose 6,6′-dibehenate) adjuvant evaluated immunogenicity in mice. We generated human angiotensin-converting enzyme 2 knock-in mice to evaluate vaccine efficacy in vivo following viral challenge. We found that 1) subdomain (SD)1 was essential for the RBD to elicit maximal immunogenicity; 2) RBDSD1 produced in mammalian HEK cells elicited better immunogenicity than did protein produced in insect or yeast cells; 3) RBDSD1 combined with the CD4 Th1 adjuvant DDA/TDB produced higher neutralizing Ab responses and stronger CD4 T cell responses than did aluminum hydroxide; 4) addition of monomeric human Fc receptor to RBDSD1 (RBDSD1Fc) significantly enhanced immunogenicity and neutralizing Ab titers; 5) the Beta version of RBDSD1Fc provided a broad range of cross-neutralization to multiple antigenic variants of concern, including Omicron; and 6) the Beta version of RBDSD1Fc with DDA/TDB provided complete protection against virus challenge in the knock-in mouse model. Thus, we have identified an optimized RBD-based subunit vaccine suitable for clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Viral VaccinesHumansAnimalsMiceSARS-CoV-2COVID-19 VaccinesAluminum HydroxideSpike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, ViralAntibodies, NeutralizingMammals

Substanzen

COVID-19 VaccinesViral VaccinesAluminum HydroxideSpike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, ViralAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • British Columbia Centre for Disease Control, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Biochemistry and Molecular Biology, Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Toronto High Containment Facility, University of Toronto, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Liam J Worrall, Bryan H Lin, Marija Vuckovic, Craig S Robb, Calem Kenward, Rashim Pal Singh, Sang Kyun Ahn, Jessica Lam, Natasha Christie-Holmes, Mario Ostrowski, Scott D Gray-Owen

Förderung

  • National Research Council of Canada

Zitieren

APA

Yu, H., Worrall, L. J., Berger, T., Petric, M., Lin, B. H., Vuckovic, M., Robb, C. S., Le, Q., Kenward, C., Dai, C., Wakeham, A., Liu, S., Snow, B., Tobin, C., Budylowski, P., Guvenc, F., You-Ten, A., Haight, J., Silvester, J., …, & Brunham, R. C. (2023). Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300282

Vancouver

Yu H, Worrall LJ, Berger T, Petric M, Lin BH, Vuckovic M, et al. Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2300282

BibTeX
@article{Yu2023,
  author = {Yu, Hong and Worrall, Liam J and Berger, Thorsten and Petric, Martin and Lin, Bryan H and Vuckovic, Marija and Robb, Craig S and Le, Quan and Kenward, Calem and Dai, Chuanbin and Wakeham, Andrew and Liu, Shaofeng and Snow, Bryan and Tobin, Chantal and Budylowski, Patrick and Guvenc, Furkan and You-Ten, Annick and Haight, Jillian and Silvester, Jennifer and Singh, Rashim Pal and Ahn, Sang Kyun and Sultana, Azmiri and Poon, Betty and Lam, Jessica and Christie-Holmes, Natasha and Ostrowski, Mario and Gray-Owen, Scott D and Kubli, Shawn and Mak, Tak and Strynadka, Natalie C J and Brunham, Robert C},
  title = {Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2300282}
}
Kostenlos starten →